| WB | 1/1000-1/2000 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | B-cell CLL/lymphoma 6 member B protein, Bcl6-associated zinc finger protein, Zinc finger protein 62, BCL6B, BAZF, ZNF62 |
| Entrez GeneID | 255877 |
| WB Predicted band size | 51.5kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | This BCL6B antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 276-302 amino acids from the Central region of human BCL6B. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide. |
+ +
以下是关于BCL6B抗体的3篇参考文献示例(注：部分信息可能需通过学术数据库核实)：
1. **文献名称**: *BCL6B suppresses tumor angiogenesis in gastric cancer by inhibiting NF-κB/VEGF signaling*
**作者**: Yamashita, K., et al.
**摘要**: 本研究利用BCL6B特异性抗体，通过免疫组化和Western blot分析，发现BCL6B在胃癌组织中表达下调，并通过抑制NF-κB通路减少血管生成，提示其抑癌功能。
2. **文献名称**: *DNA methylation and loss of BCL6B expression in colorectal cancer*
**作者**: Kudo, Y., et al.
**摘要**: 该研究通过甲基化特异性PCR和BCL6B抗体检测，证实结直肠癌中BCL6B启动子高甲基化导致蛋白表达缺失，与其临床预后不良相关。
3. **文献名称**: *BCL6B regulates T-cell differentiation and immune response*
**作者**: Moriyama, M., & Yoshimura, A.
**摘要**: 利用BCL6B抗体进行流式细胞术和ChIP实验，揭示BCL6B在调节T细胞分化中的关键作用，可能通过调控IL-2信号通路影响免疫稳态。
**备注**：以上为模拟示例，实际文献需通过PubMed或Google Scholar以关键词“BCL6B antibody”或“BCL6B function”检索确认。
The BCL6B antibody is a tool used to detect B-cell lymphoma 6 homolog B (BCL6B), a protein encoded by the *BCL6B* gene, which shares structural and functional similarities with the well-characterized BCL6 transcriptional repressor. Both belong to the BTB/POZ zinc-finger protein family and regulate gene expression by recruiting chromatin-modifying complexes. BCL6B is implicated in immune regulation, cellular differentiation, and apoptosis, though its precise biological roles remain less defined compared to BCL6. Studies suggest it may act as a tumor suppressor in certain cancers, including gastric and colorectal cancers, where its downregulation or promoter hypermethylation correlates with disease progression and poor prognosis.
BCL6B antibodies are primarily utilized in research to investigate protein expression patterns via techniques like Western blotting, immunohistochemistry (IHC), and immunofluorescence (IF). These antibodies help elucidate BCL6B’s tissue-specific distribution, particularly in lymphoid tissues, and its interaction with signaling pathways such as TGF-β and NF-κB. Dysregulation of BCL6B has also been linked to autoimmune disorders and hematological malignancies, highlighting its dual role in immune homeostasis and oncogenesis. Despite its emerging significance, BCL6B’s functional redundancy with BCL6 and context-dependent activities warrant further exploration. Reliable BCL6B antibodies are thus critical for advancing mechanistic insights and potential clinical applications in diagnostics or targeted therapies.
×
